Skip to main content
Craig Portell, MD, Oncology, Charlottesville, VA, University of Virginia Medical Center

CraigAnthonyPortellMD

Oncology • Charlottesville, VA

Hematologic Oncology

Associate Professor of Medicine, Division of Hematology/Oncology, University of Virginia

Join to view full profile

Dr. Portell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Portell's full profile

Already have an account?

Summary

  • Dr. Craig Portell is an oncologist in Charlottesville, VA and is affiliated with Emily Couric Clinical Cancer Center and University of Virginia Medical Center. He received his medical degree from St Louis University School of Medicine and has been in practice 11 years. He specializes in hematologic oncology and is experienced in immunotherapy, chronic lymphoid leukemia, mantle cell lymphoma, waldenstrom's macroglobulinemia, and Non-Hodgkin Lymphoma.

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2010 - 2013
  • Loyola University Medical Center
    Loyola University Medical CenterResidency, Internal Medicine, 2006 - 2009
  • Saint Louis University School of Medicine
    Saint Louis University School of MedicineClass of 2006

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 2013 - 2024
  • OH State Medical License
    OH State Medical License 2010 - 2014
  • IL State Medical License
    IL State Medical License 2006 - 2011
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLL  
    Matthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood

Abstracts/Posters

  • The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
    Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
    Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
    Craig A. Portell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cel... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • When Chemo Failed, CAR T-cell Therapy Took Away a Father’s Cancer
    When Chemo Failed, CAR T-cell Therapy Took Away a Father’s CancerSeptember 22nd, 2022
  • Venetoclax with Standard Chemo-Immunotherapy Induced a High Response Rate as First-Line Treatment for Mantle Cell Lymphoma and Was Generally Well Tolerated, a PrECOG Early-Phase Trial Shows
    Venetoclax with Standard Chemo-Immunotherapy Induced a High Response Rate as First-Line Treatment for Mantle Cell Lymphoma and Was Generally Well Tolerated, a PrECOG Early-Phase Trial ShowsDecember 13th, 2023

Professional Memberships

Hospital Affiliations

Dr. Craig Portell, Dr. Craig Portell, MD, Dr. C Portell, Dr. Craig Anthony Portell